High and Very High Risk cardiovascular patient journeys seems to vary from country to country, and current understanding of the process is incomplete. This real-life observational study which documents meaningful patient journey-related parameters can be expected to provide meaningful insight into the care process, country-by-country.
Suffering from hypercholesterolemia is a major health concern in Europe. Appropriate medical treatment lowers low density lipoprotein cholesterol and reduces the incidence of clinical cardiovascular events. Despite the multiple available treatments, many patients remain inadequately treated or even untreated and some lipid-lowering drugs may be associated with an increase in events like side effects or increase in diabetes. As this is a non-interventional study, only data from routine clinical practice will be documented.
Study Type
OBSERVATIONAL
Enrollment
9,559
This is a non-interventional study.
Krankenhaus St. Josef Braunau GmbH
Braunau am Inn, Austria
LKH-Univ. Klinikum Graz
Graz, Austria
Medizinische Universität Graz
Graz, Austria
Medizinische Universität Innsbruck
Innsbruck, Austria
KABEG Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Konventhospital der Barmherzigen Brüder Linz
Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants
Blood plasma samples were used to assess LDL-C levels.
Time frame: Baseline up to 12 months post-enrollment
Number of Participants Utilizing Any Treatment Modality to Manage Plasma Levels of Low Density Lipid-Cholesterol (LDL-C) in High and Very High Risk Participants Requiring Lipid Modifying Therapies (LMTs)
Clinical events were assessed based on information captured in patient files/medical records.
Time frame: Baseline up to 12 months post-enrollment
Mean Atherosclerotic Cardiovascular Disease (ASCVD)-Modifying Cholesterol Fragment Levels in High Risk and Very High Risk Dyslipidemic Participants
Blood plasma samples were used to assess ASCVD-modifying cholesterol fragment levels.
Time frame: Baseline up to 12 months post-enrollment
Mean Apolipoprotein B Levels in High Risk and Very High Risk Dyslipidemic Participants
Blood plasma samples were used to assess Apolipoprotein B levels.
Time frame: Baseline up to 12 months post-enrollment
Mean Lipid Protein A Levels in High Risk and Very High Risk Dyslipidemic Participants
Blood plasma samples were used to assess lipid Protein A levels.
Time frame: Baseline up to 12 months post-enrollment
Mean Inflammatory High-Sensitive C-Reactive Protein (hsCRP) in High Risk and Very High Risk Dyslipidemic Participants
Blood plasma samples were used to assess hsCRP levels.
Time frame: Baseline up to 12 months post-enrollment
Number of Participants With Clinical Events Associated With Treatment Modalities, For Any LMT
The safety outcome measure reports clinical events based on information captured in patient files/medical records. Participants may have reported more than one clinical event associated with any LMT.
Time frame: Baseline up to 12 months post-enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Linz, Austria
Privatklinik Wehrle-Diakonissen
Salzburg, Austria
Ordination Universitätsdozent Dr. Alexander Kober
Sankt Aegyd am Neuwalde, Austria
Ordination Dr. med. univ. Evelyn Fließer-Görzer
Sankt Stefan, Austria
Ordination Dr. Thomas Maca / Evangelische KH Wien
Vienna, Austria
...and 530 more locations